WaveMan
WaveMan · Company
APGE · Apogee Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

APGE Apogee Therapeutics (APGE) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001974640
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
197
13F, latest reported quarter
Conversions, 180 days
6
Codes C/M, not in net · $1.4M priced

What the filings say about APGE

Insiders, 180 days
-$22.6M net sold
3 sellers · 0% of sales under a 10b5-1 plan

Apogee Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Apogee Therapeutics, Inc. insiders sold a net $22.6M of stock across 137 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Dambkowski Carl
Chief Medical Officer
SELL
2026-08-07 SECtraded 2026-08-05
5,500
$737.9K
n/a
Context
  • 56 earlier Form 4 trades (code P or S) here by this insider (56 sales), the last on Jul 1, 2026.
  • The trade is 3.3% of the 168,498 shares held after it.
  • 1 other insider sold within 30 days.
  • 197 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Dambkowski Carl sold about $737.9K of APGE on Aug 5, 2026; 1 other insider sold within 30 days and 197 funds added in the latest 13F quarter.
HENDERSON MICHAEL THOMAS
Chief Executive Officer
SELL
2026-07-10 SECtraded 2026-07-08
20,000
$2.7M
n/a
Context
  • 49 earlier Form 4 trades (code P or S) here by this insider (49 sales), the last on Jun 22, 2026.
  • The trade is 2.0% of the 995,987 shares held after it.
  • 1 other insider sold within 30 days.
  • 197 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer HENDERSON MICHAEL THOMAS sold about $2.7M of APGE on Jul 8, 2026; 1 other insider sold within 30 days and 197 funds added in the latest 13F quarter.
Dambkowski Carl
Chief Medical Officer
SELL
2026-07-02 SECtraded 2026-07-01
5,500
$730.1K
n/a
Context
  • 55 earlier Form 4 trades (code P or S) here by this insider (55 sales), the last on Jun 22, 2026.
  • The trade is 3.1% of the 177,873 shares held after it.
  • 1 other insider sold within 30 days.
  • 197 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Dambkowski Carl sold about $730.1K of APGE on Jul 1, 2026; 1 other insider sold within 30 days and 197 funds added in the latest 13F quarter.
Dambkowski Carl
Chief Medical Officer
SELL
2026-06-24 SECtraded 2026-06-22
26,400
$3.5M
n/a
Context
  • 54 earlier Form 4 trades (code P or S) here by this insider (54 sales), the last on Jun 3, 2026.
  • The trade is 14.7% of the 179,248 shares held after it.
  • 1 other insider sold within 30 days.
  • 197 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Dambkowski Carl sold about $3.5M of APGE on Jun 22, 2026; 1 other insider sold within 30 days and 197 funds added in the latest 13F quarter.
HENDERSON MICHAEL THOMAS
Chief Executive Officer
SELL
2026-06-24 SECtraded 2026-06-22
80,000
$10.6M
n/a
Context
  • 48 earlier Form 4 trades (code P or S) here by this insider (48 sales), the last on Jun 10, 2026.
  • The trade is 7.9% of the 1,015,987 shares held after it.
  • 1 other insider sold within 30 days.
  • 197 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer HENDERSON MICHAEL THOMAS sold about $10.6M of APGE on Jun 22, 2026; 1 other insider sold within 30 days and 197 funds added in the latest 13F quarter.
137 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 132 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$22.6M over 180 days
-$737.9K over 90 days
below 89% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
197 funds bought in last quarter
more than 90% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
no short interest reported
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch APGE

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+151.0%12M
-1%+50%+100%+151%2025-102025-122026-022026-032026-052026-07 2026-01-22 · Harwin Peter Evan sold $133.5M2026-06-22 · HENDERSON MICHAEL THOMAS sold $10.6M2026-06-22 · Dambkowski Carl sold $3.5M2025-12-04 · HENDERSON MICHAEL THOMAS sold $3.0M2026-07-08 · HENDERSON MICHAEL THOMAS sold $2.7M2026-05-13 · HENDERSON MICHAEL THOMAS sold $1.5M2026-04-08 · HENDERSON MICHAEL THOMAS sold $1.5M2026-01-07 · Dambkowski Carl sold $1.2M2025-11-13 · HENDERSON MICHAEL THOMAS sold $932.8K2025-12-04 · Dambkowski Carl sold $817.5K2025-12-10 · HENDERSON MICHAEL THOMAS sold $758.3K2026-08-05 · Dambkowski Carl sold $737.9K2026-07-01 · Dambkowski Carl sold $730.1K2026-02-11 · HENDERSON MICHAEL THOMAS sold $723.7K2025-12-10 · HENDERSON MICHAEL THOMAS sold $706.5K2026-01-14 · HENDERSON MICHAEL THOMAS sold $676.6K2026-06-10 · HENDERSON MICHAEL THOMAS sold $633.6K2026-03-11 · HENDERSON MICHAEL THOMAS sold $621.3K2026-03-11 · HENDERSON MICHAEL THOMAS sold $615.0K2026-06-10 · HENDERSON MICHAEL THOMAS sold $556.6K2026-02-11 · HENDERSON MICHAEL THOMAS sold $481.2K2026-01-14 · HENDERSON MICHAEL THOMAS sold $447.9K2026-06-03 · Dambkowski Carl sold $432.9K2025-11-05 · Dambkowski Carl sold $311.6K2026-05-06 · Dambkowski Carl sold $310.5K2026-01-02 · Henderson Jane sold $306.8K2026-03-11 · HENDERSON MICHAEL THOMAS sold $259.3K2026-04-01 · Dambkowski Carl sold $230.6K2026-01-07 · Dambkowski Carl sold $227.8K2026-04-01 · Dambkowski Carl sold $227.5K2026-03-04 · Dambkowski Carl sold $226.8K2025-11-13 · HENDERSON MICHAEL THOMAS sold $206.8K2026-06-10 · HENDERSON MICHAEL THOMAS sold $198.9K2026-01-14 · HENDERSON MICHAEL THOMAS sold $192.3K2026-04-16 · Henderson Jane sold $180.0K2026-03-25 · Henderson Jane sold $170.0K2026-04-08 · HENDERSON MICHAEL THOMAS sold $166.5K2026-02-04 · Dambkowski Carl sold $161.0K2026-01-06 · Henderson Jane sold $160.0K2026-01-14 · HENDERSON MICHAEL THOMAS sold $152.8K2026-05-06 · Dambkowski Carl sold $152.3K2026-03-04 · Dambkowski Carl sold $149.4K2026-07-01 · CARL DAMBKOWSKI filed to sell $2.2M2026-06-22 · HENDERSON MICHAEL THOMAS filed to sell $10.6M2026-06-22 · CARL DAMBKOWSKI filed to sell $1.4M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns APGE: institutional holders (13F)

13F holdings, latest reported quarter
Venrock Adviser, LLC
8,493,321 sh
$1.1B
BlackRock, Inc.
5,507,032 sh
$730.9M
HBK INVESTMENTS L P
2,850,000 sh
$378.3M
VANGUARD CAPITAL MANAGEMENT LLC
2,572,119 sh
$341.4M
FMR LLC
2,493,137 sh
$330.9M

Congress trades in APGE

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

APGE planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
CARL DAMBKOWSKI
Filed 2026-07-01
$2.2M
HENDERSON MICHAEL THOMAS
Filed 2026-06-22
$10.6M
CARL DAMBKOWSKI
Filed 2026-06-22
$1.4M

APGE mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Return Stacked(R) Bonds & Merger Arbitrage ETF
$5.1M position · as of 2026-07-31
9.6%
Fidelity SAI Merger Arbitrage Fund
$31.8M position · as of 2026-07-31
5.0%
First Trust Merger Arbitrage Fund
$71.1M position · as of 2026-06-30
4.4%
AlphaCentric Life Sciences and Healthcare Fund
$1.5M position · as of 2026-06-30
3.3%
ALPS Medical Breakthroughs ETF
$4.7M position · as of 2026-05-31
2.9%
Comstock Capital Value Fund
$265.5K position · as of 2026-06-30
2.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
4 registered trials, 4 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 1
2 active
2
Phase 2
2 active
What changed recently
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity
2026-09-25 · Completion moved 2026-09 → 2026-09-17
Phase 1
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$1.3M
$16.0M
$855.9K
+256%
+42%
2024
$13.2M
$35.1M
$5.1M
+113%
+6%
2023
$8.7M
$35.3M
$4.6M
+32%
+7%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $22.6M sold by insiders over 180 days, 197 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

APGE financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$249.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
n/a
no equity line filed
Return on assets
-29.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-34.1%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no share count filed
FCF yield
n/a
no share count filed
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-09-02. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$285.6M-$216.9M-$93.0Mn/a
Net income-$255.8M-$182.1M-$84.0Mn/a
EPS (diluted)-4.22-3.30-3.36n/a
Operating cash flow-$227.4M-$171.2M-$74.8Mn/a
Cash$131.5M$141.8M$118.3M$151.9M
SEC XBRL, fiscal years, as known on 2026-10-28

APGE Stock Sonar score 3/7 axes

Find similar shapesCompare

APGE ranks highest on institutional and government (90th percentile) and profitability (63rd), and lowest on insider conviction (5th), among Pharma & Biotech peers.

Profitability
63
Inputs
  • Return on equityno equity line filed
  • Return on assets-29.5% · 61 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-34.1% · 65 pct, sector of 576
Insider conviction
5
Inputs
  • Net Form 4 buying (codes P and S), 180d-$22.6M · 9 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
90
Inputs
  • Funds adding, latest quarter197 · 90 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
4 not measured: Financial health, Growth, Risk and compliance, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Risk and compliance needs 1 of 4 inputs, 0 present: needs two 10-Ks with a Risk Factors section (not 20-F filers or stubs); no short interest or no free float on file; revenue under $50M or not filed, so a count cannot be scaled to size
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

APGE filings, in plain words

Are Apogee Therapeutics insiders buying or selling APGE?

In the 180 days to 2026-10-28, Apogee Therapeutics insiders were net sellers, a net $22.6M across purchases and sales reported on Form 4, by 3 sellers.

Read the full summary

In the 180 days to 2026-10-28, Apogee Therapeutics insiders were net sellers of APGE, a net $22.6M across purchases and sales reported on Form 4 by 3 sellers. None of the 19 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies